Dianthus Therapeutics Statistics
Share Statistics
Dianthus Therapeutics has 29.60M shares outstanding. The number of shares has increased by -51.52% in one year.
| Shares Outstanding | 29.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.23M |
| Failed to Deliver (FTD) Shares | 31 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.10M, so 17.22% of the outstanding shares have been sold short.
| Short Interest | 5.10M |
| Short % of Shares Out | 17.22% |
| Short % of Float | 24.67% |
| Short Ratio (days to cover) | 23.02 |
Valuation Ratios
The PE ratio is -1.23 and the forward PE ratio is -8.49.
| PE Ratio | -1.23 |
| Forward PE | -8.49 |
| PS Ratio | 18.97 |
| Forward PS | 250.3 |
| PB Ratio | 0.32 |
| P/FCF Ratio | -1.45 |
| PEG Ratio | n/a |
Enterprise Valuation
Dianthus Therapeutics Inc. has an Enterprise Value (EV) of -78.14M.
| EV / Earnings | 1.79 |
| EV / Sales | -27.65 |
| EV / EBITDA | 1.62 |
| EV / EBIT | 1.62 |
| EV / FCF | 2.11 |
Financial Position
The company has a current ratio of 18.42, with a Debt / Equity ratio of 0.
| Current Ratio | 18.42 |
| Quick Ratio | 18.42 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.25 |
| Cash Flow / Debt | -88.4 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -28.43%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -28.43% |
| Revenue Per Employee | 53.32K |
| Profits Per Employee | -821.79K |
| Employee Count | 53 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 228.63% in the last 52 weeks. The beta is 0, so Dianthus Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 228.63% |
| 50-Day Moving Average | 26.25 |
| 200-Day Moving Average | 26.19 |
| Relative Strength Index (RSI) | 42.93 |
| Average Volume (20 Days) | 261.59K |
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of $2.83M and earned -$43.55M in profits. Earnings per share was $-8.45.
| Revenue | 2.83M |
| Gross Profit | 2.47M |
| Operating Income | -48.17M |
| Net Income | -43.55M |
| EBITDA | -48.17M |
| EBIT | -48.17M |
| Earnings Per Share (EPS) | -8.45 |
Balance Sheet
The company has $132.32M in cash and $585.00K in debt, giving a net cash position of $131.74M.
| Cash & Cash Equivalents | 132.32M |
| Total Debt | 585.00K |
| Net Cash | 131.74M |
| Retained Earnings | -89.42M |
| Total Assets | 354.25M |
| Working Capital | 271.78M |
Cash Flow
In the last 12 months, operating cash flow was -$36.86M and capital expenditures -$110.00K, giving a free cash flow of -$36.97M.
| Operating Cash Flow | -36.86M |
| Capital Expenditures | -110.00K |
| Free Cash Flow | -36.97M |
| FCF Per Share | -7.17 |
Margins
Gross margin is 87.44%, with operating and profit margins of -1.70K% and -1.54K%.
| Gross Margin | 87.44% |
| Operating Margin | -1.70K% |
| Pretax Margin | -1.54K% |
| Profit Margin | -1.54K% |
| EBITDA Margin | -1.70K% |
| EBIT Margin | -1.70K% |
| FCF Margin | -1.31K% |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.56% |
| FCF Yield | -5.26% |
Analyst Forecast
The average price target for DNTH is $44, which is 85.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $44 |
| Price Target Difference | 85.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Sep 12, 2023. It was a backward split with a ratio of 1:16.
| Last Split Date | Sep 12, 2023 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | 25.13 |
| Piotroski F-Score | 3 |